Opthea Limited (NASDAQ: OPT)
$2.14
+0.0500 ( +2.39% ) 18.3K
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Market Data
Open
$2.14
Previous close
$2.09
Volume
18.3K
Market cap
$191.60M
Day range
$2.04 - $2.18
52 week range
$1.60 - $4.40
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 4 | Nov 09, 2023 |
6-k | Quarterly Reports | 4 | Oct 30, 2023 |
6-k | Quarterly Reports | 4 | Oct 27, 2023 |
6-k | Quarterly Reports | 96 | Oct 27, 2023 |
6-k | Quarterly Reports | 4 | Oct 02, 2023 |
20-f | Annual reports | 189 | Sep 28, 2023 |
6-k | Quarterly Reports | 2 | Sep 28, 2023 |
6-k | Quarterly Reports | 4 | Sep 07, 2023 |
6-k | Quarterly Reports | 12 | Aug 31, 2023 |
6-k | Quarterly Reports | 3 | Aug 28, 2023 |